Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.
- Published In:
- European journal of medicinal chemistry, 247, 115036 (2023)
- Authors:
- Yuan, Yongliang, Yan, Zhiming(3), Lao, Qifang, Jiang, Neng, Wu, Shuangmin, Lu, Qinpei, Han, Jing, Zhao, Songfeng
- Database ID:
- RPEP-07604
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07604APA
Yuan, Yongliang; Yan, Zhiming; Lao, Qifang; Jiang, Neng; Wu, Shuangmin; Lu, Qinpei; Han, Jing; Zhao, Songfeng. (2023). Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.. European journal of medicinal chemistry, 247, 115036. https://doi.org/10.1016/j.ejmech.2022.115036
MLA
Yuan, Yongliang, et al. "Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist.." European journal of medicinal chemistry, 2023. https://doi.org/10.1016/j.ejmech.2022.115036
RethinkPeptides
RethinkPeptides Research Database. "Discovery of a potent and long-acting Xenopus GLP-1-based GL..." RPEP-07604. Retrieved from https://rethinkpeptides.com/research/yuan-2023-discovery-of-a-potent
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.